News Related to Lutetium (177Lu) Vipivotide Tetraxetan

Related coverage linked through entity extraction aliases.

ESMO Guidelines Endorse Lutetium Therapy; New Data on PSMA Prediction, DOAC Safety

Jun 01, 2026

European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.

PSMA-PET Imaging Linked to Earlier Advanced Therapies in Prostate Cancer

May 08, 2026

PSMA-PET imaging leads to earlier use of advanced therapies like ARPIs in prostate cancer patients compared to bone scans. Real-world data on 177Lu-PSMA-617 shows comparable efficacy to the VISION trial in mCRPC patients.